Molecular Basis of Weak D Phenotypes: Presented at the 25th Congress of the International Society of Blood Transfusion held in Oslo on June 29, 1998 and published in abstract form in Vox Sang 74:55, 1998 (suppl).

THE RHESUS D (RhD) antigen (ISBT 004.001; RH1) carried by the RhD protein is the most important blood group antigen determined by a protein. It is still the leading cause of hemolytic disease of the newborn.1 About 0.2% to 1% of whites have red blood cells with a reduced expression of the D antigen (weak D, formerly D^u).2-4 A small fraction of weak D samples are explained by qualitatively altered RhD proteins, called partial D,5 and frequently caused byRHD/RHCE hybrid alleles, a flurry of which was recently published (reviewed in Huang6). Another fraction is caused by the suppressive effects of Cde haplotypes in trans position.7 These weak D likely possess the normalRHD allele, because the carriers’ parents and children often express a normal RhD antigen density. Such weak D show only a minor reduction of RhD antigen expression, were loosely called high grade D^u, and often typed today as normal RhD, because of the increased sensitivity of monoclonal anti-D.8 

The majority of weak D phenotypes is caused by genotype(s) located either at the Rhesus genes’ locus itself or in its proximity, because the weak D expression is inherited along with the RhD phenotype.2 Besides the mere quantitative reduction, no qualitative differences could be discerned in the RhD antigen of this group. Two recent studies addressed the molecular cause of the prevalent weak D phenotypes. Both groups, Rouillac et al9and Beckers et al,10 performed reverse-transcriptase-polymerase chain reaction (RT-PCR) and claimed unanimously that their sequencing of RHD cDNA in weak D samples showed a normal RHD coding sequence. However, no definite molecular cause of the weak D expression was established and the proposed mechanisms differed. Using semiquantitative RT-PCR, Rouillac et al9 reported reduced steady-state levels of RHDtranscripts and claimed that their observations provided direct evidence of a quantitative difference in RhD between normal and weak D red blood cells. In contrast, Beckers et al10,11 found no differences in the amounts of RHD transcripts, further excluded an excess of splice variants,10 12 and concluded that weak D is not caused by regulatory defects of the transcription process.

Screening of random weak D samples by PCR for RHD specific polymorphisms confirmed PCR amplification patterns representative for a normal RHD allele.13,14 However, evidence was accumulating that the underlying molecular basis can be heterogeneous,13 and some weak D may carry structurally abnormal RHD alleles. In four of 44 English weak D, noRHD specific intron 4 PCR amplicons13 were detected, and in one of 90 Northern German weak D, no RHDspecific exon 5 PCR amplicons14 were detected. In a similar more extensive molecular screen by PCR-SSP,15 we found about 2.5% structural abnormalities in more than 600 weak D samples (Gassner et al, manuscript submitted).

These observations prompted us to search for further allelic variation among weak D samples by sequencing. In contrast to the commonly accepted knowledge,6,13 16-19 we found that all weak D samples tested had mutations in RHD exon sequences.

EDTA- or citrate-anticoagulated blood samples were collected from white blood donors and characterized as weak D during donor typing in accordance with published standards (D^u-test)20as described.3 The donors were not known to be related. D category VI samples were excluded from this study.

DNA was prepared as described previously.15 Nucleotide sequencing was performed with a DNA sequencing unit (Prism dye terminator cycle-sequencing kit with AmpliTaq FS DNA polymerase; ABI 373A, Applied Biosystems, Weiterstadt, Germany). Nucleotide sequencing of genomic DNA stretches representative for all 10 RHD exons and parts of the promoter was accomplished using primers (Table 1) and amplification procedures (Table 2) that obviated the need for subcloning steps.

RHD exons 3 to 7 and 9 carry at least one RHD-specific nucleotide, which was used to verify the RHD origin of the sequences. For exon 1, characteristic nucleotides in the adjacent parts of intron 1 were used.21 For exon 8, the RHDspecificity of the PCR amplification was checked by RHDnonspecific sequencing of the informative exon 9, because exons 8 and 9 were amplified as a single PCR amplicon (Table 2). Exon 2 and 10 were amplified in an RHD- specific way (Table 2) based on publishedRHD-specific nucleotide sequences (EMBL nucleotide sequence data base accession numbers U66340 and U66341)22,23; no PCR amplicons were obtained in RhD⁻ controls (data not shown). All normal D and weak D samples showed a G at position 65424 and a C at position 1036,22 supporting the notion25 that the alternatively described C²² and T,24 respectively, were sequencing errors.

PCR-RFLP methods were developed to characterize distinct nucleotide substitutions detected in five RHD alleles: the C to G substitution at position 8 led to the loss of a Sac I restriction site in amplicons obtained with re01 and re11d (G to A at 29, loss of Msp I site, re01/re11d; C to A at 446, loss ofAlu I site, rb20d/rb21d; T to G at 809, loss of Alw44 I site, rf51/re71; G to C at 1154, introduction of Alu I site, re82/re93). Conditions for the rf51/re71 PCR reaction were as shown in Table 2. The rb20d/rb21d reaction was done with nonproofreading Taq-polymerase (Boehringer Mannheim, Mannheim, Germany or Qiagen, Hilden, Germany) with 20 seconds denaturation at 94°C, 30 seconds annealing at 60°C, and 30 seconds extension at 72°C. The other PCR reactions were performed with nonproofreading Taq-polymerase with 20 seconds denaturation at 94°C, 30 seconds annealing at 55°C, and 1 minute extension at 72°C.

Another four RHD alleles were detected by a standard RHPCR-SSP15: the RHD(T201R,F223V) andRHD(S182T,K198N,T201R) alleles lacked specific amplicons for RHD exon 4, the RHD(G307R) and RHD(A276P) alleles lacked those for RHD exon 6. For all other weak D types, the authenticity of the point mutations was checked by nucleotide sequencing of independent PCR amplicons.

To check for mutations in the RHD promoter, we amplified a 675-bp region using primer pair rb13 and rb11d (Table 2). The promoter region was sequenced using primers re02 and re01 starting at nucleotide position −545 relative to the first nucleotide of the start codon.

In RHD intron 3, there was a G/C polymorphism that determined aHae III-RFLP at position −371 relative to the intron 3/exon 4 junction. To check this polymorphism, we amplified the 3′ part of intron 3 using the RHD specific primer pair rb46 and rb12 and digested the PCR products with Hae III. InRHD intron 6, there was a variable length TATT tandem repeat starting 1,915 bp 3′ of exon 6. To examine this tandem repeat, we amplified the full-length intron 6 using the RHD-specific primer pair rf51 and re71 and used primer rg62 for sequencing. The haplotype association of the Hae III site was tested in 10 CCDee, 8 ccDEE, 10 ccDee (W16C⁺), and 10 ccDee (W16C⁻) samples. The haplotype association of the TATT repeat was tested in 3 CCDee, 3 ccDEE, 1ccDEe, 2 ccDee (W16C⁺), and 2 ccDee (W16C⁻) samples. In control samples, the presence and absence of the Hae III site was linked to 9 and 8 TATT repeats, respectively. The Hae III site was present in the 20 CDe haplotypes and 18 of 20 cDe haplotypes tested, but absent in 15 of 16 cDE haplotypes (CDe v cDE,P < .001; cDe v cDE, P < .001; CDev cDe, not significant; 2 × 2 contingency tables, Fisher’s exact test).

In D^IV type III exons 6 to 9 were amplified and sequenced using primers that were specific for RHCE andRHD. Therefore, primer re71 was substituted by primer rb7; primer re621 by rb26; and primer re52 by re74. To demonstrate anRHD-RHCE hybrid allele, we amplified intron 5 in aRHD-specific way using the exon 5 PCR reaction (Table 2) and sequenced the breakpoint region using primer rb15.

RNA was prepared and reverse-transcribed as published.21cDNA was amplified in a nested PCR reaction (High Fidelity PCR system, Boehringer Mannheim, Mannheim, Germany) with external primers RR1 and RR4 and internal primers Rh5 and RR3 and subcloned into pMos (pMos-T-kit; United States Biochemical, Cleveland, OH).

In the 416 codons of the RHD gene excluding the start codon, 2,766 missense and 919 silent mutations can occur yielding an expected proportion of 0.254 of silent mutations. A total of 782 of the missense mutations and 437 of the silent mutations are transitions resulting in an expected proportion of 0.36 of silent transitions. A total of 41 missense and 30 silent mutations are located in CpG doublets resulting in a proportion of silent mutations in CpG doublets of 0.42. Independent of any possible excess of transitions or mutations in CpG doublets, random nucleotide changes should therefore lead to a minimal frequency of silent mutations of 0.254. Nonsense mutations and mutations in the start codon were assumed to prevent RhD expression13 and are excluded from the calculations.

The phenotype frequencies of weak D types among weak D samples were calculated separately for each serologic (CcDEe) weak D phenotype and combined according to the frequencies of the serologic weak D phenotypes.3 ccDEE weak D samples were assumed to be cDE/cdE. Phenotype frequencies in the population were calculated from the population frequency of the weak D phenotype in Southwestern Germany.3 These data are minimal estimates, because some samples with only moderately weakened D expression may have been inadvertantly grouped to normal strength D. Haplotype frequencies were calculated using a haplotype frequency of 0.411 for RhD⁻ haplotypes3 assuming that all weak D samples were heterozygous. For weak D types 1 to 5, 9, 13, and 15, more than one proband was observed rendering the haplotype association trivial. Weak D type 11 was observed in a ccDee phenotype implying a cDe haplotype. Weak D types 6 to 8 and 12 were observed in single CcDee samples and assumed to be CDe/cde, which is correct in more than 96% of samples according to the haplotype frequencies in the population investigated.3 Weak D types 10, 14, and 16 were observed in single ccDEe samples and assumed to be cDE/cde, which is correct in more than 98% of samples.3 Hence, the probability that an cDE versus cDe misassignment corrupted the analysis of haplotype-specific polymorphisms was less than 0.05.

The position of the transmembraneous helices was based on an analysis of RhD by the PredictProtein server prediction of transmembrane helices (http://www.embl-heidelberg.de/predictprotein/predictprotein.html,26helix 1 to 11) and TMpred (http://ulrec3.unil.ch/software/TMPRED_form.html,27 helix 12) with minor modifications localizing position 110 and 226 on the cell surface and 12 in the membrane in accordance with other published models.28,29 There is experimental evidence30 31 for intracellular positions of the amino and carboxytermini.

A method for RHD-specific sequencing of the 10 RHDexons and their splice sites was developed. In a sequential analysis strategy, blood samples with weak expression of antigen D, including a random survey of 161 samples from blood donors in Southwestern Germany, were checked by this method, PCR-RFLP (Fig1), and RHD PCR-SSP.15 We found 18 RHDalleles with distinct nucleotide changes coding for amino acid substitutions (Table 3). One allele lackedRHD exons 6 to 9 concordant with a RHD-CE-D hybrid allele dubbed hereby D^IV type III. Another allele was DHMi.32 Of the remaining 16 alleles, 14 showed single, but distinct previously unknown missense mutations. None of the encoded variant amino acids occurred at the corresponding positions in the RhCE proteins. Two alleles exhibited multiple nucleotide changes typical for the RHCE gene, which were interspersed byRHD-specific sequences.

A set of 161 samples with weak expression of antigen D was gathered from random blood donors in Southwestern Germany. D category VI samples, but no other partial D, were excluded by serologic methods. Two samples represented known partial D (DHMi32 and D category IV33). Without any exception, all samples could be assigned to distinct RHD alleles with aberrant RHD exon sequences (Table 3). We propose that the new molecular weak D types should be referred to by trivial names, eg, weak D type 1, or by their molecular structures, eg, RHD(V270G). The weak D type 1 was the most frequent known RHD allele (f = 1:277) with aberrant coding sequence, exceeding even the D^VII allele frequency.34 

The amino acid substitutions observed in weak D types with single missense mutations were not evenly distributed in the RhD protein (Fig 2). The majority of substitutions occurred in the region of amino acid positions 267 to 397. Single and multiple amino acid substitutions in smaller portions of the RhD protein around positions 2 to 13, 149, and 179 to 225 (weak D type 4 and 14) were also found in weak D alleles. According to the current RhD loop model, the involved amino acids were positioned in the transmembraneous and intracellular protein segments (Fig 3).

RHD specific sequencing of the 10 RHD exons predicted regular RhD protein sequences in six control samples with a normal antigen D expression; 545 bp 5′ of the start codon comprising part of the RHD promoter were sequenced in one sample of each weak D type, DHMi, and D^IV type III. No deviation from the normal RHD promoter sequence35 was found.

The frequency of altered RhD proteins in weak D (159 of 159) and normal D samples (0 of 6) was statistically significantly different (P< .0001, 2 × 2 contingency table, Fisher’s exact test). A normal RhD coding sequence in the weak D phenotype was expected to occur in less than 1.9% (upper limit of 95% confidence interval, Poisson distribution). These amino acid substitutions are unlikely to reflect random nucleotide changes, because a random mechanism would lead to a frequency of silent mutations of at least 0.254, while we observed only one silent mutation among a total of 18 mutations in weak D alleles (P = .037, binomial distribution).

In intron 3 and intron 6, we detected polymorphic RHD sequences that differed between the prevalent RHD alleles of the CDe and cDE haplotypes (Table 4). Weak D alleles were identical to the prevalent alleles of the same RHhaplotype in regard to these polymorphisms, with the single exception of weak D type 4 displaying a unique intron 6 repeat sequence. The conservation of these haplotype-specific RHD polymorphisms suggested that weak D alleles evolved independently.

The weak D phenotype is represented by a group ofRHD⁺ genotypes that code in their vast majority for altered RhD proteins associated with a reduced RhD expression on the red blood cells’ surface. Our population-based study dismissed unequivocally the possibility of one distinct antigen D^uand showed in contrast to previous conjectures, that weak D alleles do generally possess mutations in RHD exon sequences. We provided statistical evidence that the missense mutations observed in the alleles of all weak D types are the probable cause for the reduced antigen D expression.

We suggest a causal relation of missense mutations and reduced RhD protein integration: (1) weak D alleles evolved independently in the different haplotypes, each distinct event being associated with a change in the RhD protein sequence; (2) no sample occurred with a normal RHD sequence despite observation of 13 different alleles in 161 samples; (3) type and distribution of the observed nucleotide substitutions was not compatible with the null hypothesis of random changes; (4) missense mutations causing reduced RhD expression fit nicely into the current model of RhD membrane integration.

Rh proteins occur in a complex with the Rh50 protein, and the expression of the Rh/Rh50 complex depends on the presence of both intact Rh5036 and Rh37,38 proteins. Missense mutations in the Rh50 protein are known to cause reduced expression of the Rh complex.36,39 Amino acid substitutions in the RhD protein might hence affect the expression of the RhD/Rh50 complex. A formal experimental proof of causality would involve expression systems. The only currently available system40 has, so far, not been shown to predict expression in a quantitative way.

Based on the distribution and kind of amino acid substitutions, a general picture of the relationship of RhD structure and RhD expression arose: all amino acid substitutions in weak D were located in the intracellular or transmembraneous parts of the RhD protein. Known RhD alleles with exofacial substitutions32,41-43 were discovered by virtue of their partial D antigen, but may display discrete (DNU and D^VII) to moderate (D^II, DHR, and DHMi) reductions in RhD expression.43-45 Most substitutions reported in this study were nonconservative and the introduced amino acids, in particular proline, likely disrupted the secondary or tertiary structure. Two weak D alleles (type 2 and 11) were associated with conservative substitutions indicating that the involved amino acid regions at positions 295 and 385 may be particularly important for an optimal RhD membrane integration. In two alleles (type 4 and type 14), parts of exon 4 and 5 were substituted by the corresponding parts of the RHCE gene. Similar exchanges occurred in D^VI type I and D^VI type II that exhibited a considerably reduced RhD protein expression45 also. Previous paradoxical observations can be explained, if the N152T substitution in exon 3 is considered to facilitate the membrane integration: (1) D^IIIa,46 differing from weak D type 4 by the N152T substitution only, has a normal RhD antigen density,45 and (2) D^IIIc, D^IVa, and D^VI type III harboring the N152T substitution have enhanced antigen densities21 45 compared with their appropriate controls (normal RhD and D^VI type II).

Our genomic sequencing method was optimized to detect missense mutations. The approach obviated the laborious need to obtain full-length cDNA and to differentiate missense mutations from misincorporated nucleotides introduced during PCR and subcloning steps. The demonstration of missense mutations by genomic RHDsequencing definitively refuted the current dogma9,10 of a normal RHD allele in weak D phenotypes. The possibility of additional aberrations, eg, multiple hybrid genes with complementaryRHD exon patterns, was formally excluded for the most frequent weak D type 1 representing about 0.3% of all RHD alleles by sequencing the full-length cDNA. Our results are incongruous with two earlier reports asserting normal RHD coding sequences in three weak D samples from France9 and in an unspecified number of weak D samples from the Netherlands.10 Possibly, these investigators missed the mutations because of technical problems of the traditional approach based on cDNA. Alternative explanations are very unlikely: (1) There might be regional variations in the causes of weak D, although other Rh alleles as frequent as the prevalent weak D alleles do not differ much in whites. (2) Both groups may have inadvertently investigated high grade D^u that are due to a suppressive effect of Cde and expected to possess a normal coding sequence. We excluded the possibility that we investigated some rare, previously uncharacterized partial D instead of weak D, because the phenotypes described by us occurred with a cumulative frequency of 0.41% and, therefore, accounted for the majority of weak D phenotypes. Weak D type 4 was partially characterized by Legler et al.14 These investigators performed sevenRHD-specific PCR reactions that were not affected by most mutations in weak D types. Their approach was not designed to exclude the kind of genetic diversity that is actually present in our weak D phenotypes.

Our findings implied that there is no well-defined borderline between weak D and partial D that has an aberrant RHD coding sequence, lacks specific D epitopes, and may be associated with an allo–anti-D. The observation of anti-D production in Rhesus positive recipients is too rare, even for some D categories, to base a classification on this event. Serologic discrimination of qualitative and quantitative abnormalities is prone to mistakes in samples with strongly reduced D antigen densities. A normal exofacial Rh sequence may be accompanied by alloimmunization, as exemplified by the VS antigen of the RhCE protein caused by the transmembraneous L245V substitution.47 

Although multiple publication13,14,45,48-56 suggested a heterogeneity of weak D, a serologic classification of the majority of weak D phenotypes has not been successful. There was even no defined borderline between normal D and weak D.50,51,57,58 Our findings made the classification of weak D phenotypes feasible and their classification will allow us to correlate distinct alleles with clinical data. In the case that patients carrying certain molecular weak D types were prone to develop anti-D, our classification might guide a Rhesus negative transfusion policy. The availability of weak D samples that are characterized in regard to molecular structure and RhD antigen densities will promote the quality assurance of anti-D reagents. They should reliably type probands as RhD⁺, whose RhD proteins are not prone to frequent anti-D immunization.3 Therefore, the use of RhD⁻red blood cell units for transfusions to weak D patients, which has been justified by a presumed potential for anti-D immunization, can finally be reduced to a minimum, which can be scientifically deduced.

Some RHD alleles described in the present study were more prevalent than previously known RHD alleles. The potential for a broader relevance in research was opened, as it became feasible to determine in a massive way the frequencies of molecularly defined rare alleles in natural populations. Poisson-like allele distributions were predicted by mathematical models59 that could so far not be checked in any real population. We observed two alleles (type 4 and 14) with multiple nucleotide substitutions in the RHD gene that were characteristic for the RHCE gene, but may not be explained by a single gene conversion event. This observation pointed to more complicated mechanisms shaping the allele polymorphism of homologous genes, which are frequent throughout the genomes.

We thank Olga Zarupski and Katharina Schmid for expert technical assistance.